Celldex Therapeutics (Celldex Therapeutics) Change In Receivables : $-2.28 Mil (TTM As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Celldex Therapeutics Change In Receivables?

Celldex Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was $-2.38 Mil. It means Celldex Therapeutics's Accounts Receivable increased by $2.38 Mil from Sep. 2023 to Dec. 2023 .

Celldex Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $-2.28 Mil. It means Celldex Therapeutics's Accounts Receivable increased by $2.28 Mil from Dec. 2022 to Dec. 2023 .

Celldex Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was $2.63 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Celldex Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 58.05.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Celldex Therapeutics's liquidation value for the three months ended in Dec. 2023 was $389.11 Mil.

Celldex Therapeutics Change In Receivables Historical Data

The historical data trend for Celldex Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Change In Receivables Chart

Celldex Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

2.27

-0.79

1.57

-0.18

-2.28

Celldex Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-0.16	-0.97	1.20	-0.13	-2.38

Celldex Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.28 Mil.

Celldex Therapeutics (NAS:CLDX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Celldex Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.628	/	4.131	*	91
=	58.05

2. In Ben Graham's calculation of liquidation value, Celldex Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Celldex Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	423.598	-	36.456	+	0.75 * 2.628	+	0.5 * 0
=	389.11

Celldex Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Celldex Therapeutics (Celldex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (NAS:CLDX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

TCE2:Germany

Address

53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827

Website

https://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Executives

Garry Arthur Neil	director	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Tibor Keler	officer: Sen. VP & Ch Scientific Off.	30 PARK ROAD, OTTSVILLE PA 18942
Sarah Cavanaugh	officer: SVP of Corp. Affairs & Admin.	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Diane C. Young	officer: SVP, Chief Medical Officer	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Anthony S Marucci	director, officer: President and CEO	66 COLD HILL DRIVE, MENDAHM NJ 07945
Richard M. Wright	officer: Sr. VP & CCO	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Samuel Bates Martin	officer: SVP and CFO	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Margo Heath-chiozzi	officer: SVP of of Regulatory Affairs	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Elizabeth Crowley	officer: SVP, Chief Product Dev Officer	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
Freddy A. Jimenez	officer: SVP & General Counsel	C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON NJ 08827
James J Marino	director	C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Gerald Phd Mcmahon	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114